Search results

Order by most recent / most popular / relevance

Results: 1-5 of 5

Global Pricing Newsletter: volume two

Sidley Austin LLP
-
China, Global, United Kingdom, USA
-
February 27 2013

Pharmaceutical and biologic manufacturers operate in an increasingly global economy where legal developments in one market may have cascading impacts

Basel III Additional Tier 1 Going-Concern Capital and Tier 2 Capital

Sidley Austin LLP
-
Global, USA
-
December 21 2010

As Warren Buffett quipped, "Only when the tide goes out do you discover who's been swimming naked."

Trade negotiators seek comment on elimination of pharmaceutical import duties

Sidley Austin LLP
-
Global, USA
-
April 23 2010

Over 9,000 pharmaceutical and chemical intermediates enjoy duty-free treatment under the customs regime of the United States and other countries that participate in the World Trade Organization (WTO) Pharmaceutical Agreement

Hybrid capital product development: Focusing on Tier 1 and other hybrid capital products

Sidley Austin LLP
-
European Union, Global, USA
-
March 23 2010

It is our pleasure to provide you with the eleventh edition of Sidley's publication on hybrid capital product development

Deforestation: global, EU and US initiatives create opportunities and threats for businesses

Sidley Austin LLP
-
European Union, Global, USA
-
June 30 2009

The global fight to address climate change is increasingly focused on protecting and managing the world’s forests

Search results

Global Pricing Newsletter: volume two

Basel III Additional Tier 1 Going-Concern Capital and Tier 2 Capital

Trade negotiators seek comment on elimination of pharmaceutical import duties

Hybrid capital product development: Focusing on Tier 1 and other hybrid capital products

Deforestation: global, EU and US initiatives create opportunities and threats for businesses

Current Search

Suggested Facets

Author

Jurisdiction

Workarea